Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Enabling Genomic Technologies and Screening Asia 2014
Conferences  \  Enabling Genomic Technologies and Screening Asia 2014  \  Agenda  \  Alex Matter
RegisterLogin

Alex Matter's Biography


Alex Matter, CEO, Experimental Therapeutics Centre & D3 A*STAR

Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore.
Previously, he was Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009.
Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation.
Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec® and more recently, Tasigna®, building and leading the teams that discovered these and several other anticancer drugs.

Alex Matter Image

Novel Medicines for Unmet Medical Needs - Translational R&D in Singapore

Thursday, 11 September 2014 at 09:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

ETC has assembled all the technologies that are needed to perform state-of-the-art drug discovery. The principle is to form a partnership with a premier academic group working on a set of well-defined, validated targets. The goal is to discover novel, attractive and feasible Preclinical Development Candidates. Subsequently, a complementary facility (D3) will take up such projects and bring them through preclinical development that will enable to reach an IND (CTC). Such a drug candidate can then enter early clinical trials, to reach a Proof-of-Concept (PoC) that is based on evidence of tolerability, plausible pharmacokinetics and biomarker evidence of attractive pharmacodynamics.


Agenda is not currently available
Add to Calendar ▼2014-09-11 00:00:002014-09-12 00:00:00Europe/LondonEnabling Genomic Technologies and Screening Asia 2014Enabling Genomic Technologies and Screening Asia 2014 in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors
Related Conferences
Point-of-Care, Biosensors and Rapid Dx Europe 2024
Location: Rotterdam, The Netherlands
Date: 24/06/2024 - 25/06/2024


Innovations in Flow Cytometry & Extracellular Vesicles 2024
Location: Laguna Hills, California
Date: 18/11/2024 - 20/11/2024


Circulating Biomarkers and Extracellular Vesicles Europe 2024
Location: Rotterdam, The Netherlands
Date: 24/06/2024 - 25/06/2024